SCHEMBL1022128

SCHEMBL1022128

Cc1ccc[n+]([O-])n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907034 0.70 KMT2A (0.37)
SCHEMBL10950773 0.70
SCHEMBL11883930 0.70
SCHEMBL4923326 0.70
SCHEMBL13876270 0.70
SCHEMBL18104373 0.67 ALDH1A1 (0.44)
SCHEMBL7346076 0.67 KDM4E (0.32)
SCHEMBL15998509 0.66 OPRM1 (0.33)
SCHEMBL7788128 0.65
SCHEMBL18093536 0.63 MAPK1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195480-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2025-06-19 US disclosed
US-12109198-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators Fulcrum Therapeutics, Inc. (US) 2024-10-08 US disclosed
US-20240139163-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2024-05-02 US disclosed
CN-114144230-B Macrocyclic azolopyridine derivatives as EED and PRC2 modulators 弗尔康医疗公司 2024-04-23 CN disclosed
US-11590111-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators Fulcrum Therapeutics, Inc. (US) 2023-02-28 US disclosed
US-20220160686-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2022-05-26 US disclosed
CN-114144230-A Macrocyclic azolopyridine derivatives as EED and PRC2 modulators 弗尔康医疗公司 2022-03-04 CN disclosed
EP-3938050-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. (US) 2022-01-19 EP disclosed
US-10973805-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators Fulcrum Therapeutics, Inc. (US) 2021-04-13 US disclosed
US-20200360353-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2020-11-19 US disclosed
EP-1844044-B1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-07-21 EP disclosed
US-7678815-B2 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
WO-2009055331-A2 BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 SCHERING CORPORATION (US) 2009-04-30 WO disclosed
EP-1844044-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-17 EP disclosed
US-7241760-B2 Central nervous system disorders; psycholgical disorders; antiepi;eptic agents; schizophrenia; Alzheimer's disease; cognition activators; analgesics HOFFMANN-LA ROCHE INC. (US) 2007-07-10 US disclosed
US-20060160857-A1 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2006-07-20 US disclosed
WO-2006074884-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-07-20 WO disclosed
EP-1670784-A1 HETEROARYL-SUBSTITUTED IMDAZOLE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-06-21 EP disclosed
WO-2004111040-A1 HETEROARYL-SUBSTITUTED IMDAZOLE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-12-23 WO disclosed
US-20040254179-A1 Heteroaryl-substituted imidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-12-16 US disclosed